Given the high relevance of tamoxifen for breast cancer patients worldwide, this work assessed the risk for subtarget CSS,min ENDX in patients of different biogeographical groups [28] at tamoxifen standard dosing based on their respective frequency of different CYP2D6 alleles [29] by applying pharmacometric modelling and simulation. This evidence concerns the gene CYP2D6 and breast carcinoma.